These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 34425232)

  • 1. Development of agomelatine nanocomposite formulations by wet media milling.
    Vardaka E; Andreas O; Nikolakakis I; Kachrimanis K
    Eur J Pharm Sci; 2021 Nov; 166():105979. PubMed ID: 34425232
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Nanocrystal formulations of mebendazole employing quality by design and molecular level insights by atomistic simulations.
    Vardaka E; Kachrimanis K
    Drug Dev Ind Pharm; 2024 Aug; 50(8):735-749. PubMed ID: 39212605
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Optimization of formulation and process parameters for the production of carvedilol nanosuspension by wet media milling.
    Medarević D; Djuriš J; Ibrić S; Mitrić M; Kachrimanis K
    Int J Pharm; 2018 Apr; 540(1-2):150-161. PubMed ID: 29438724
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A quality-by-design study to develop Nifedipine nanosuspension: examining the relative impact of formulation variables, wet media milling process parameters and excipient variability on drug product quality attributes.
    Patel PJ; Gajera BY; Dave RH
    Drug Dev Ind Pharm; 2018 Dec; 44(12):1942-1952. PubMed ID: 30027778
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Overcoming the Solubility Barrier of Ibuprofen by the Rational Process Design of a Nanocrystal Formulation.
    Ouranidis A; Gkampelis N; Vardaka E; Karagianni A; Tsiptsios D; Nikolakakis I; Kachrimanis K
    Pharmaceutics; 2020 Oct; 12(10):. PubMed ID: 33066680
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Investigation of Formulation and Process Parameters of Wet Media Milling to Develop Etodolac Nanosuspensions.
    Karakucuk A; Celebi N
    Pharm Res; 2020 May; 37(6):111. PubMed ID: 32476048
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Review of nanosuspension formulation and process analysis in wet media milling using microhydrodynamic model and emerging characterization methods.
    Tian Y; Wang S; Yu Y; Sun W; Fan R; Shi J; Gu W; Wang Z; Zhang H; Zheng A
    Int J Pharm; 2022 Jul; 623():121862. PubMed ID: 35671851
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The Impact of Process and Formulation Parameters on the Fabrication of Efavirenz Nanosuspension to Improve Drug Solubility and Dissolution.
    Rashed M; Dadashzadeh S; Bolourchian N
    Iran J Pharm Res; 2022 Dec; 21(1):e129409. PubMed ID: 36942076
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Production of aprepitant nanocrystals by wet media milling and subsequent solidification.
    Toziopoulou F; Malamatari M; Nikolakakis I; Kachrimanis K
    Int J Pharm; 2017 Nov; 533(2):324-334. PubMed ID: 28257885
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Enhanced recovery and dissolution of griseofulvin nanoparticles from surfactant-free nanocomposite microparticles incorporating wet-milled swellable dispersants.
    Bhakay A; Azad M; Vizzotti E; Dave RN; Bilgili E
    Drug Dev Ind Pharm; 2014 Nov; 40(11):1509-22. PubMed ID: 23981202
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Nanosuspensions of a poorly soluble investigational molecule ODM-106: Impact of milling bead diameter and stabilizer concentration.
    Singhal M; Baumgartner A; Turunen E; van Veen B; Hirvonen J; Peltonen L
    Int J Pharm; 2020 Sep; 587():119636. PubMed ID: 32659405
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Insight into the Formation of Glimepiride Nanocrystals by Wet Media Milling.
    Medarević D; Ibrić S; Vardaka E; Mitrić M; Nikolakakis I; Kachrimanis K
    Pharmaceutics; 2020 Jan; 12(1):. PubMed ID: 31936609
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Redispersible fast dissolving nanocomposite microparticles of poorly water-soluble drugs.
    Bhakay A; Azad M; Bilgili E; Dave R
    Int J Pharm; 2014 Jan; 461(1-2):367-79. PubMed ID: 24333905
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Exploring the influence factors and improvement strategies of drug polymorphic transformation combined kinetic and thermodynamic perspectives during the formation of nanosuspensions.
    Meng T; Qiao F; Ma S; Gao T; Li L; Hou Y; Yang J
    Drug Dev Ind Pharm; 2021 Dec; 47(12):1867-1880. PubMed ID: 35362347
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Preparation and characterization of fast dissolving pullulan films containing BCS class II drug nanoparticles for bioavailability enhancement.
    Krull SM; Ma Z; Li M; Davé RN; Bilgili E
    Drug Dev Ind Pharm; 2016; 42(7):1073-85. PubMed ID: 26567632
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hybrid nanocrystal-amorphous solid dispersions (HyNASDs) as alternative to ASDs for enhanced release of BCS Class II drugs.
    Rahman M; Arevalo F; Coelho A; Bilgili E
    Eur J Pharm Biopharm; 2019 Dec; 145():12-26. PubMed ID: 31622652
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Increase in Dissolution Rate of Zotepine via Nanomilling Process - Impact of Dried Nanocrystalline Suspensions on Bioavailability.
    Parmar K; Oza K
    AAPS PharmSciTech; 2021 Dec; 23(1):20. PubMed ID: 34907489
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Spray drying of drug-swellable dispersant suspensions for preparation of fast-dissolving, high drug-loaded, surfactant-free nanocomposites.
    Azad M; Arteaga C; Abdelmalek B; Davé R; Bilgili E
    Drug Dev Ind Pharm; 2015; 41(10):1617-31. PubMed ID: 25347144
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Optimization of Performance Variables of Exemestane Nanosuspension Using Box-Behnken Design to Improve Dissolution and Oral Bioavailability.
    Parmar K; Shah J
    Curr Drug Deliv; 2021; 18(8):1148-1161. PubMed ID: 33438540
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Particle Size Tailoring of Quercetin Nanosuspensions by Wet Media Milling Technique: A Study on Processing and Formulation Parameters.
    Cheshmehnoor P; Bolourchian N; Abdollahizad E; Derakhshi A; Dadashzadeh S; Haeri A
    Iran J Pharm Res; 2022 Dec; 21(1):e130626. PubMed ID: 36915402
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.